viewLancor Scientific

Medtech disruptor Lancor Scientific strengthens its marketing team

Lancor Scientific's CEO Aamir Butt and Head of Marketing & Global Access Dr. Donald De Korte tell Proactive London how the company is now poised, after 10 years of R&D, to deliver low cost cancer screening to millions.
Lancor recently gained permission to work in a cancer research laboratory in Austria and have made inroads into low income countries such as Zimbabwe, working in rural areas and taking their instant results cancer testing kit with them.
Dr. De Korte is a new addition to the Lancor team and Butt is thrilled to have that expertise on board as De Korte's experience in disease control in Sub-Saharan Africa is, he says, second to none.
Dr. De Korte also regards Lancor's fusion of blockchain technology and healthcare as nothing short of revolutionary, saying that blockchain "really puts the patient first".
He goes on to say...''I believe strongly that our technology and the way it's connected to blockchain will really revolutionise access to cancer screening and ultimately the appropriate management of cancer in the developing world''.


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Lancor Scientific named herein, including the promotion by the Company of Lancor Scientific in any Content on the Site, the Company receives...



Lancor Scientific to have its screening device approved for six cancers by March

Lancor Scientific's Roland Schlesinger updates Proactive London's Andrew Scott on latest developments with their cancer screening device. He says they've already got one cancer device approved with five more soon to follow. ''We're in the process of moving towards mass production...

on 22/5/19

2 min read